Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Vanda Pharmaceuticals Inc VNDA

Healthcare Biotechnology
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in... see more

Bullboard (NDAQ:VNDA)

View:
Post by whytestockson Apr 17, 2024 3:45pm

Neuropsychiatric-Focused Vanda Pharmaceuticals Rejects Futur

News; $VNDA Neuropsychiatric-Focused Vanda Pharmaceuticals Rejects Future Pak's Takeover Bid Valued Up To $7.75/Share | BenzingaOn Wednesday,@Vanda Pharmaceuticals Inc.@(NASDAQ:VNDA) confirmed ...more  
31
Post by whytestockson Apr 17, 2024 3:30pm

Why Vanda Pharmaceuticals Stock Is Skyrocketing Today

JUST IN: $VNDA Why Vanda Pharmaceuticals Stock Is Skyrocketing Today2024-04-17 11:53:00 ET Shares of Vanda Pharmaceuticals (NASDAQ: VNDA) were skyrocketing 37.8% higher as of 10:09 a.m. ET on ...more  
26
Post by whytestockson Apr 17, 2024 3:15pm

Vanda Pharmaceuticals Adopts Limited Duration Stockholder Ri

News; $VNDA Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan | BenzingaWASHINGTON, April 17, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (@Vanda@ or the @Company@) (NASDAQ ...more  
25
Post by whytestockson Apr 17, 2024 2:30pm

Vanda Pharmaceuticals Adopts Limited Duration Stockholder Ri

Just In: $VNDA Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights PlanVanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan PR Newswire WASHINGTON , April 17, 2024 ...more  
22
Post by whytestockson Apr 17, 2024 2:15pm

Vanda Pharmaceuticals Confirms Rejection of Unsolicited Take

BREAKING NEWS: $VNDA Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future PakVanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future ...more  
33
Post by JGrabaron May 31, 2022 9:59am

$VNDA -Settlement

$VNDA -On May 19, 2022, Vanda Pharmaceuticals agreed to settle a securities fraud class action complaint (the “Complaint”) for $11.5 Million. https://grabarlaw.com/the-latest/vanda ...more  
70
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities